Mark Aloysius Morgan

Mark Aloysius Morgan

faculty photo
Professor CE of Obstetrics and Gynecology
Chief, Division of Gynecologic Oncology, University of Pennsylvania Health System
Director of Gynecologic Oncology Chemotherapy, University of Pennsylvania
Director of Gynecologic Oncology Clinical Research , University Of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Chief, Division Of Gynecologic Oncology
University Of Pennsylvania Health System
3400 Civic Center Boulevard, 10th Floor PCAM South Tower
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
B.A. (Microbiology)
Rutgers College, 1977.
M.D. (Medicine)
Downstate Medical Center (SUNY) Cum Laude, 1982.
Post-Graduate Training
Intern, Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1982-1983.
Resident, Obstetrics and Gynecology, Department of Obstetrics and Gynecology Hospital of the University of Pennsylvania Philadelphia, PA , 1983-1986.
Postdoctoral Fellow, Division of Gynecologic Oncology University of Pennsylvania School of Medicine Philadelphia, PA , 1986-1988.
Clinical Fellow, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1986-1988.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical trials

Description of Clinical Expertise

Gynecologic Oncology; Urogynecology

Selected Publications

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM: Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or perineum: an open label, single-arm, phase 2 study. The Lancet 4(2):134-140, 2013.

Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 61(5):629-641. , 2012.

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, DeGeest K, Yamada SD, Waggoner S, Coleman, RL, Walker JL, Mannel RS: A Phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in unreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 121(2):264-68, 2011 Notes: PMCID: PMC3081997/NIHMSID: NIHMS270582.

Morgan, MA: Intraperitoneal chemotherapy for ovarian cancer. Adv Exp Med Biol 622:145-51, 2008.

Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ: Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group. Gynecologic Oncology 110:329-335, 2008.

Morgan MA, Polan ML, Melecot HH, Debru B, Sleemi A, Husain A: Experience with a low-pressure colonic pouch (Mainz II) urinary diversion for irreparable vesicovaginal fistula and bladder extrophy in East Africa. Int Urogynecol J 20:1163-1168, 2009.

Buckingham L, Koenig A, Ko EM, Brensinger CM, Latif N, Hummel C, Zhang X, Morgan MA, Burger RA, Giuntoli II RL.: Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment. Int J Gynecol Cancer. Page: (7):1177-1181, Sep 2019.

Wethington SL, Shah PD, Martin LP, Tanyi JL, Latif NA, Morgan MA, Torigian DA, Pagan C, Rodriguez D, Domchek SM, Drapkin R, Shih I-M, Smith S, Dean E, Armstrong DK, Gaillard S, Simpkins F : Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. ASCO Annual Meeting virtual Jun 2021.

Tanyi JT, Chon HS, Morgan MA, Chambers SK, Butler KA, Langstraat CL, Powell MA, Randall LM, Vahrmeijer AL, Winer IS, Wenham RM: Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. ASCO Annual Meeting *virtual. Jun 2021.

Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A.: Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight. 2020 Aug 20;5(16):e136773. doi: 10.1172/jci.insight.136773. PMID: 32814714; PMCID: PMC7455139. Aug 2020.

Nasioudis D, Mastroyannis SA, Latif NA, Haggerty AF, Cory L, Giuntoli II RL, Kim SH, Morgan MA, Ko EM: : Impact of systematic lymphadenectomy at the time of interval debulking surgery on the survival of patients with advanced stage epithelial ovarian carcinoma following neoadjuvant chemotherapy. (Poster) Society of Gynecologic Oncology Annual meeting *virtual. Mar 2021.

Dimitrios Nasioudis, Benjamin B Albright, Ashley F Haggerty, Emily M Ko, Sarah H Kim, Mark A Morgan, Nawar A Latif: Survival following minimally invasive radical hysterectomy for patients with cervical carcinoma and tumor size ≤2 cm. Am J Obstet Gynecol. Page: 224(3):317-318.e2. doi, Mar 2021.

back to top
Last updated: 01/04/2024
The Trustees of the University of Pennsylvania